Zobrazeno 1 - 10
of 1 390
pro vyhledávání: '"Anti-Xa"'
Autor:
Alex M. Lynch, Laura K. Ruterbories, Yao Zhu, Frank Fialkiewicz, Mark G. Papich, Marjory B. Brooks, Robert Goggs
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 38, Iss 6, Pp 3242-3254 (2024)
Abstract Background Comparative pharmacokinetics and pharmacodynamics (PK/PD) of apixaban and rivaroxaban have not been studied in dogs and the propensity of these drugs to cause hypercoagulability after discontinuation is unknown. Hypothesis Compare
Externí odkaz:
https://doaj.org/article/1dc9e8a7b54a44ce8ccfe4ab20cf54ff
Autor:
А. S. Petrikov, Т. V. Vavilova, А. V. Vardanyan, М. N. Zamyatin, I. А. Zolotukhin, К. V. Lobastov, Е. V. Roitman, Е. I. Seliverstov, Yu. М. Stoyko, I. А. Suchkov
Publikováno v:
Фармакоэкономика, Vol 17, Iss 2, Pp 251-278 (2024)
On March 15, 2024, in Moscow, the Russian Phlebological Association and the National Association of Specialists in Thrombosis, Clinical Hemostasiology and Hemorheology organized a meeting of the Council of Experts during the Russian Forum on Thrombos
Externí odkaz:
https://doaj.org/article/af03c899590b433e988626bb5f97aac4
Autor:
Isabelle Gouin-Thibault, Alexandre Mansour, Michael Hardy, Pierre Guéret, Emmanuel de Maistre, Virginie Siguret, Adam Cuker, François Mullier, Thomas Lecompte
Publikováno v:
TH Open, Vol 08, Iss 03, Pp e297-e307 (2024)
Externí odkaz:
https://doaj.org/article/0010def081174c3593e038609e5a1970
Autor:
Alexander Tinchon, Joana Brait, Sascha Klee, Uwe Graichen, Christian Baumgartner, Oliver Friedrich, Elisabeth Freydl, Stefan Oberndorfer, Walter Struhal, Barbara Hain, Christoph Waiß, Dagmar Stoiber
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionAnti-Xa serves as a clinical surrogate for assessing the efficacy and bleeding risk in patients treated with enoxaparin for thromboembolic events. Evidence from the literature and empirical observations suggest that patients are underdose
Externí odkaz:
https://doaj.org/article/ae74c80d88db47048c176713e9c630b2
Autor:
A. Hellemans, N. Devriendt, L. Duchateau, K. M. J. Devreese, F. De Somer, T. Bosmans, G. Mampaey, P. Smets
Publikováno v:
Veterinary Medicine and Science, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract Background No guidelines for administering and monitoring anticoagulants intraprocedurally are currently available in dogs, despite the prevalence of procedures necessitating systemic anticoagulation with heparin. Objectives To evaluate an a
Externí odkaz:
https://doaj.org/article/0c1a3b7a42c042bea19cd7170ca4788b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tadahiro Kobayashi, Satoko Saito, Masayuki Takada, Kento Sakaguchi, Kazunori Takahashi, Ken Tanaka, Kaneyuki Kawamae, Masaki Nakane
Publikováno v:
Case Reports in Acute Medicine, Vol 6, Iss 1, Pp 13-18 (2023)
Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive intoxication with 70 tablets of apixaban and have presented the clinical course of the associated anti-Xa
Externí odkaz:
https://doaj.org/article/7ea2916d40274f09acb2fec3e0498772
Publikováno v:
Атеротромбоз, Vol 13, Iss 1, Pp 46-57 (2023)
Introduction. Lengthening the period of direct oral anticoagulant (DOAC) withdrawal before intervention is not allowed. Chronic kidney disease (CKD), impaired liver function, extremely low or high body mass, chronic heart failure (CHF), and age > 90
Externí odkaz:
https://doaj.org/article/03e97d69c95149df81b09922849727b6
Autor:
Julien Lanoiselée, Jérémy Mourer, Marie Jungling, Serge Molliex, Lise Thellier, Julien Tabareau, Emmanuelle Jeanpierre, Emmanuel Robin, Sophie Susen, Benoit Tavernier, André Vincentelli, Edouard Ollier, Mouhamed Djahoum Moussa
Publikováno v:
Pharmaceutics, Vol 16, Iss 6, p 770 (2024)
Background. Unfractionated heparin is administered in patients undergoing veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Anticoagulation monitoring is recommended, with an anti-activated factor X (anti-Xa) targeting 0.3 to 0.7 IU/mL. Ow
Externí odkaz:
https://doaj.org/article/23a4c0a37f2a4cb49e46ab42f9fdc579
Autor:
V. M. Kosman, M. V. Karlina, N. M. Faustova, E. A. Ezhova, I. G. Kotelnikova, V. G. Makarov, M. N. Makarova
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 13, Iss 1, Pp 89-103 (2023)
According to current regulatory views, a comparative study of the pharmacodynamics (PD) of low molecular weight heparin (LMWH) products and confirmation of their equivalence require comparing three PD markers: the anti-Xa activity, the anti-IIa activ
Externí odkaz:
https://doaj.org/article/a8e1acb6678b42c1a694bf109e9783b8